A new drug application for povorcitinib is expected to be filed in late 2025 to early 2026 to treat adult patients with ...
Biosimilars are essential healthcare equalizers, but their regulation is overly complicated due to lobbying by makers of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback